Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy

doi:10.4251/wjgo.v17.i2.100167

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (409)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

HTML

164

Figures (1-3)

Tables (1-4)

Sum=240

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=124

Publishing Process of This Article

Item

Count

Browse

Download

Sum=27

Feb 15, 2025 (publication date) through Feb 1, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Feb 15, 2025; 17(2): 100167
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.100167

Table 2 Overall summary of efficacy in third-line chemotherapy

	(n = 141)
Best response, n (%)
PR	2 (1.4)
SD	35 (24.8)
PD	84 (59.6)
NA	20 (14.2)
Disease control rate (CR + PR + SD)	37 (26.2)
Median survival from third-line chemotherapy, weeks (95%CI)
OS3	15.3 (12.9-17.7)
PFS (n = 110)	7.3 (6.3-8.3)
Median survival from diagnosis, months (95%CI)
OS	19.0 (16.6-21.4)

CI: Confidence interval; CR: Complete response; NA: Not available; OS: Overall survival; OS3: Overall survival at third-line chemotherapy; PD: Progressive disease; PFS: Progression-free survival; PR: Partial response; SD: Stable disease.

Citation: Kim B, Kim J, Yang S, Ahn J, Jung K, Lee JC, Hwang JH. Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. World J Gastrointest Oncol 2025; 17(2): 100167
URL: https://www.wjgnet.com/1948-5204/full/v17/i2/100167.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i2.100167